David E. Cohen - 05 Nov 2025 Form 3 Insider Report for Evommune, Inc.

Role
Director
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Issuer symbol
EVMN on NYSE
Transactions as of
05 Nov 2025
Net transactions value
$0
Form type
3
Filing time
05 Nov 2025, 20:02:55 UTC
Previous filing
18 Apr 2023
Next filing
12 Nov 2025
SEC
View on sec.gov

Key filing fact

David E. Cohen filed Form 3 for Evommune, Inc. on 05 Nov 2025.

Key facts

  • This page summarizes David E. Cohen's Form 3 filing for Evommune, Inc..
  • 0 reported transactions and 5 derivative rows are listed below.
  • Filing timestamp: 05 Nov 2025, 20:02.

Change

  • Previous filing in this sequence was filed on 18 Apr 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC Source

Ownership activity is grounded in SEC Form 3 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001347383 Primary reporting owner

Cohen David E

Relationship
Director
Address
C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Signature date
05 Nov 2025

Transactions Table

EVMN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
17,609
Date
05 Nov 2025
Ownership
Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

EVMN holding Derivative

Series Seed Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
05 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,056
Exercise price
Footnotes
F1
EVMN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
05 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
61,356
Exercise price
$3.07
Footnotes
F2
EVMN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
05 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,869
Exercise price
$3.84
Footnotes
F3
EVMN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
05 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,869
Exercise price
$1.71
Footnotes
F4
EVMN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
05 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
11,739
Exercise price
$2.99
Footnotes
F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series Seed Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's initial public offering, all shares of Series Seed Preferred Stock will be converted into shares of Common Stock of the Issuer.
F2 One fourth (1/4) of the shares subject to the option award vested on May 11, 2023 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F3 One fourth (1/4) of the shares subject to the option award vested on May 12, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F4 One fourth (1/4) of the shares subject to the option award vested on January 6, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F5 One fourth (1/4) of the shares subject to the option award shall vest on December 17, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .